Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Stopped Study terminated due to slow recruitment and insufficient further funding.
Conditions
- Advanced Malignant Pleural Mesothelioma
Interventions
- DRUG: Pembrolizumab
- RADIATION: Stereotactic Body Radiotherapy (SBRT)
Sponsor
Royal Marsden NHS Foundation Trust
Collaborators